A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's Disease (NCT06881836)
A Phase II, 26-week, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of ONO-2020 in Patients With Mild to Moderate Alzheimer's Disease
🩺 Plain-English Summary (8th-Grade Level)
This is a Phase 2, double-blind, parallel-group, placebo-controlled study to assess safety, tolerability, pharmacokinetics, and efficacy of ONO-2020 in participants with mild to moderate Alzheimer's disease (AD). This study aims to determine whether administering ONO-2020, an epigenetic regulator, may improve cognitive functions like memory and cognition in individuals with Alzheimer's disease dementia.
Who can join: Review the eligibility criteria below.
Location: University of Alabama at Birmingham — Birmingham, Alabama
Age range: 55 Years to 85 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (96 Sites)
Showing the first 25 of 96 sites.
- University of Alabama at Birmingham — Birmingham, Alabama
- Banner Alzheimer's Institute (BAI) — Phoenix, Arizona
- Clinical Endpoints — Scottsdale, Arizona
- Banner Sun Health Research Institute — Sun City, Arizona
- Center for Neurosciences-Research — Tucson, Arizona
- Profound Research LLC at The Neurology Center of Southern California — Carlsbad, California
- Neurology Center of North Orange County — Fullerton, California
- Stanford University — Palo Alto, California
- Sunwise Clinical Research — Walnut Creek, California
- CenExel Rocky Mountain Clinical Research — Englewood, Colorado
- Brain Matters Research — Delray Beach, Florida
- Velocity Clinical Research, Hallandale Beach — Hallandale, Florida
- Premier Clinical Research Institute; Inc. — Miami, Florida
- Quantum Clinical Trials — Miami Beach, Florida
- Suncoast Clinical Research — New Port Richey, Florida
- Renstar Medical Research — Ocala, Florida
- Charter Research - Orlando — Orlando, Florida
- Accel Research Sites - Brain and Spine Institute — Port Orange, Florida
- USF Health Byrd Alzheimer's Institute — Tampa, Florida
- ForCare Clinical Research — Tampa, Florida
- Charter Research - The Villages — The Villages, Florida
- Conquest Research LLC — Winter Park, Florida
- Sandhill Research, LLC d/b/a Accel Research Sites - NeuroStudies CRU — Decatur, Georgia
- CenExel iResearch, LLC — Savannah, Georgia
- Velocity Clinical Research, Boise — Meridian, Idaho
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Alzheimer Disease
- The Use of Memantine for Prevention of Alzheimer's Disease — Charlottesville, Virginia
- Investigation of Inflammation Using [C-11]-CS1P1 — St Louis, Missouri
- Sleep Disturbance and Emotion Regulation Brain Dysfunction as Mechanisms of Neuropsychiatric Symptoms in Alzheimer's Dementia — Palo Alto, California
- A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (HOPE Study) — Gilbert, Arizona
- High Frequency Light and Sound Stimulation to Improve Brain Functions in Alzheimer's Disease — Cambridge, Massachusetts
- A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease — Phoenix, Arizona
Explore by condition: All Alzheimer Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.